Sharda Cropchem Limited has announced strong financial results for the quarter and year ended March 31, 2026. The company achieved a record annual revenue of ₹5,268 crore, representing a 22% increase over the previous year. Driven by a robust 13.3% growth in agrochemical volumes, the company also reported its highest-ever profit after tax of ₹681 crore, underscoring its success in maintaining high operational efficiencies and global market expansion.
Annual Financial Performance
For the full financial year 2026, Sharda Cropchem reported a consolidated revenue of ₹5,268 crore, a significant 22% growth compared to ₹4,320 crore in FY25. This performance was anchored by substantial growth in the agrochemical segment, which constitutes 90% of the total revenue. Profit After Tax (PAT) for the year reached a record high of ₹681 crore, marking a 124% increase from ₹304 crore in the prior year.
Q4 FY26 Highlights
The fourth quarter ending March 31, 2026, contributed strongly to the annual figures, with revenues rising 13% to ₹2,065 crore. The agrochemical segment delivered a 14% revenue increase to ₹1,927 crore. Gross margins improved impressively by 750 basis points to 37.3%, while the EBITDA for the quarter climbed 75% to ₹513 crore.
Operational Efficiency and Strategic Expansion
The company continues to leverage its asset-light business model, focusing on the identification of generic molecules, dossier preparation, and registration. As of March 31, 2026, Sharda Cropchem has secured 3,011 registrations and filed 1,004 additional applications globally. With a presence in over 80 countries, supported by 525 distributors and a 500+ member sales force, the company remains committed to expanding its footprint across Europe, NAFTA, and Latin America.
Strong Balance Sheet
The company maintains a healthy financial position, reporting Total Equity of ₹3,137 crore as of March 31, 2026, up from ₹2,501 crore the previous year. Improvements in working capital management resulted in a reduction of 20 days, bringing the cycle down to 98 days. Furthermore, the company reported a robust Return on Capital Employed (RoCE) of 30.4%, reflecting its disciplined approach to capital allocation and operational execution.
Source: BSE
